Jeanette Weidner, Principal Accounting Officer and Principal Financial Officer of Gain Therapeutics, Inc., filed an initial statement of beneficial ownership on Form 3 with the SEC on October 30, 2026, with an event date of October 28, 2026.

Key Highlights

  • Reporting person: Jeanette Weidner, identified in the filing as Principal Accounting Officer and Principal Financial Officer of Gain Therapeutics, Inc.
  • Event date: The date of the event requiring the statement is listed as October 28, 2026.
  • No securities held: According to the filing, no securities are beneficially owned by the reporting person.
  • No derivative securities: Table II of the filing lists no derivative securities, including no options, warrants, or convertible securities.
  • Issuer: Gain Therapeutics, Inc., trading on NASDAQ:GANX, is identified as the issuer.
  • Filing basis: The form was filed by one reporting person pursuant to Section 16(a) of the Securities Exchange Act of 1934.

Weidner Reports No Beneficial Ownership Upon Joining Gain Therapeutics

Jeanette Weidner submitted an initial statement of beneficial ownership to the SEC in connection with her role as Principal Accounting Officer and Principal Financial Officer at Gain Therapeutics, Inc. (NASDAQ:GANX). The filing, signed October 30, 2026, reflects an event date of October 28, 2026, which the filing identifies as the date of the event requiring the statement.

According to the filing, both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, contain no entries. The remarks section of the filing states explicitly: "No securities are beneficially owned." This means the filing records zero direct or indirect beneficial ownership of any class of Gain Therapeutics securities as of the event date.

The filing also notes an Exhibit 24, a Power of Attorney, as part of the exhibit list. Weidner is identified solely as an officer of the issuer, with the director and 10% owner checkboxes left unchecked on the form.

What Was Disclosed

Jeanette Weidner filed an initial beneficial ownership statement as Principal Accounting Officer and Principal Financial Officer of Gain Therapeutics, Inc. The filing reports no beneficially owned securities, either direct or indirect, in any form as of October 28, 2026.